Fortress Biotech, Inc.’s subsidiary Caelum Biosciences, has entered a biopharmaceutical manufacturing agreement with Patheon for process development and current good manufacturing practices (cGMP) production of Caelum’s lead therapy CAEL-101.   The agreement will support Phase II/III studies of CAEL-101 for the treatment of amyloid light chain (“AL”) amyloidosis, a rare systemic disorder that leads to the buildup of amyloid proteins in and around tissues, nerves and organs, resulting in organ...